Keryx Biopharmaceuticals to Present at the Bank of America 2008 Health Care Conference
Mr. Weiss' presentation, which will take place on Thursday, May 15th at11:10am PT, will be webcast live and will be accessible from the InvestorInformation page of the Company's Website at http://investors.keryx.com. Anarchived version of the webcast will be available following the conclusion ofthe live presentation.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development andcommercialization of medically important, novel pharmaceutical products forthe treatment of life-threatening diseases, including renal disease andcancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-basedcompound that has the capacity to bind to phosphate and form non-absorbablecomplexes. Zerenex is currently in Phase 2 clinical development for thetreatment of hyperphosphatemia (elevated phosphate levels) in patients withend-stage renal disease, or ESRD. The Company is also developing KRX-0401(perifosine), a novel, potentially first-in-class, oral anti-cancer agent thatmodulates Akt, a protein in the body associated with tumor survival andgrowth. KRX-0401 also modulates a number of other key signal transductionpathways, including the JNK and MAPK pathways, which are pathways associatedwith programmed cell death, cell growth, cell differentiation and cellsurvival. KRX-0401 is currently in Phase 2 clinical development for multipletumor types. The Company also has an in-licensing and acquisition programdesigned to identify and acquire additional drug candidates. Keryx isheadquartered in New York City.KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: firstname.lastname@example.org
SOURCE Keryx Biopharmaceuticals, Inc.
You May Also Like